USPTO Art Unit 1615 Prosecution Statistics

Art Unit Information

Art Unit: 1615
Group: 1610
Tech Center: 1600
Total Cases: 17,164
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19343371THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSSeptember 2025February 2026Allow510NoNo
19326225DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODSSeptember 2025February 2026Allow610NoNo
19319209AQUEOUS COMPOSITIONSeptember 2025February 2026Allow510YesNo
19316708SELF-REGULATING PHOTO-CURABLE COOLING HYDROGEL AND PREPARATION METHOD AND APPLICATION THEREOFSeptember 2025January 2026Allow401YesNo
19311629UROLITHIN GUMMY (PECTIN) FORMULATIONSAugust 2025February 2026Allow510NoNo
19302463SOLID DOSAGE FORMS OF ELAFIBRANORAugust 2025March 2026Allow710YesNo
19301647IMMEDIATE RELEASE MULTILAYER TABLETAugust 2025December 2025Allow410NoNo
19300134DURABLE ANTI-FUNGAL AND ALGAE RESISTANT COATINGSAugust 2025November 2025Allow300YesNo
19297675METHOD FOR WEED CONTROL IN LAWN OR TURFAugust 2025March 2026Allow710YesNo
19264750TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHANJuly 2025January 2026Allow610NoNo
19263736METHOD OF TREATING CANCER USING CaV2O6/CaSiO3/g-C3N4 NANOCOMPOSITEJuly 2025September 2025Allow300NoNo
19251149MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFJune 2025September 2025Allow310NoNo
19243333DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODSJune 2025March 2026Allow910YesNo
19238194PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEJune 2025March 2026Allow920YesNo
19206964COMPOSITION AND METHOD FOR TREATING HEARING LOSSMay 2025September 2025Allow510YesNo
18852937CATIONIC LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOFApril 2025November 2025Allow1420NoNo
19181843ATOMOXETINE HYDROCHLORIDE ORAL SUSPENSION AND USE THEREOFApril 2025September 2025Allow510NoNo
19182311ATOMOXETINE HYDROCHLORIDE ORAL SUSPENSION AND USE THEREOFApril 2025July 2025Allow310YesNo
19174583TAMPER RESISTANT DOSAGE FORMSApril 2025July 2025Allow310NoNo
19169459BURDOCK SEED OIL-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAMEApril 2025August 2025Allow410NoNo
19097443BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSApril 2025September 2025Allow610YesNo
19097811INJECTABLE CARBOPLATIN FORMULATIONSApril 2025August 2025Allow410YesNo
19095550CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAMEMarch 2025September 2025Allow620NoNo
19078590Adhering Lozenge with High Amount of Sparsely Soluble Active IngredientMarch 2025October 2025Allow810NoNo
19077685MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESMarch 2025May 2025Allow200YesNo
19071625MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAMEMarch 2025January 2026Allow1010NoNo
19065576METHODS OF TREATING GASTROINTESTINAL DISEASES AND DISORDERSFebruary 2025July 2025Allow510YesNo
19060326PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOFFebruary 2025August 2025Allow610NoNo
19047536NOVEL FORMULATION FOR LACOSAMIDEFebruary 2025August 2025Allow610YesNo
19039751BIOADHESIVE FOR MEDICAL AND DENTAL APPLICATIONSJanuary 2025August 2025Allow610YesNo
19026572DISPOSABLE SYSTEM AND METHOD FOR PREPARING A COMPRESSED HYDROGELJanuary 2025August 2025Allow710NoNo
19030589AMINO ACID COMPOSITIONSJanuary 2025January 2026Allow1210NoNo
19029026EPINEPHRINE LIQUID FORMULATIONSJanuary 2025September 2025Allow810NoNo
19025220GELS FOR INSULIN DELIVERYJanuary 2025April 2025Allow310NoNo
19026269POROUS HYDROGEL MICROSPHERES AND PREPARATION METHODS THEREOFJanuary 2025February 2026Abandon1320NoNo
19013003PHARMACEUTICAL SOLUTION OF AMLODIPINEJanuary 2025June 2025Allow510NoNo
19009331SUSPENSION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVEJanuary 2025October 2025Allow920YesNo
19005284DRUG POWDERIZATION WITHIN VIALSDecember 2024June 2025Allow610NoNo
19004850MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFDecember 2024June 2025Allow610NoNo
19004480IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOFDecember 2024June 2025Allow610NoNo
18986791DUAL ACTING POLYMERS IN AN OSMOTIC FILM FOR TOPICAL APPLICATION TO TREAT INFLAMMATORY DISEASES AND CYTOKINE RELEASE SYNDROMEDecember 2024November 2025Abandon1110NoNo
18979844LOW SODIUM OXYBATE ONCE NIGHTLY COMPOSITIONDecember 2024September 2025Allow911NoNo
18978361Liquid supramolecular self-recognition system of low-pH azelaic acid, and preparation method therefor and application thereofDecember 2024April 2025Allow411YesNo
18977541COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDSDecember 2024March 2025Allow300YesNo
18977838LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOFDecember 2024April 2025Allow410NoNo
18975144MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFDecember 2024February 2025Allow210NoNo
18964814PHARMACEUTICAL COMPOSITIONSDecember 2024January 2026Allow1420YesNo
18953603TAMPER RESISTANT DOSAGE FORMSNovember 2024February 2025Allow310NoNo
18950649BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSNovember 2024February 2025Allow310NoNo
18946268PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOFNovember 2024November 2025Allow1230NoNo
18926566COENZYME Q10 COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOF IN CARDIO-PROTECTIONOctober 2024January 2025Allow300NoNo
18926688NICLOSAMIDE FORMULATIONS AND METHODS OF USEOctober 2024August 2025Allow1021YesNo
18921291PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEOctober 2024March 2025Allow510YesNo
18911732MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFOctober 2024December 2024Allow210NoNo
18911045ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANSOctober 2024August 2025Allow1000YesNo
18897657OPHTHALMIC FORMULATIONS AND METHODS OF USESeptember 2024January 2025Allow410NoNo
18893806PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810YesNo
18893805TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONSSeptember 2024April 2025Allow610NoNo
18893790TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERYSeptember 2024May 2025Allow710YesNo
18893796STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18893798TREATMENT OF OCULAR INFLAMMATION WITH OPHTHALMIC COMPOSITIONSSeptember 2024July 2025Allow910NoNo
18893810PH STABILIZED OPHTHALMIC COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18889070MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024January 2025Allow400NoNo
18889023MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024December 2024Allow300YesNo
18889055MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024February 2025Allow500NoNo
18830440COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALSSeptember 2024March 2025Allow620YesNo
18816200PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOFAugust 2024January 2025Allow510NoNo
18801899CENTANAFADINE MULTIPHASIC CONTROLLED-RELEASE PHARMACEUTICAL FORMULATIONAugust 2024November 2025Allow1540YesNo
18799983COMPOSITION AND METHOD FOR TREATING HEARING LOSSAugust 2024April 2025Allow811YesNo
18797717Mycophenolate Oral SuspensionAugust 2024December 2024Allow410NoNo
18797696Mycophenolate Oral SuspensionAugust 2024November 2024Allow310YesNo
18794390ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONSAugust 2024February 2025Allow620YesNo
18791632MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFAugust 2024October 2024Allow210NoNo
18789870MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFJuly 2024September 2024Allow210NoNo
18790336STABLE EPINEPHRINE SUSPENSION FORMULATION FOR INHALATION WITH HFO PROPELLANTJuly 2024August 2025Allow1210YesNo
18780575SUBCUTANEOUS INJECTION METHOD FOR PAIN TREATMENTJuly 2024October 2024Allow300YesNo
18779499PHARMACEUTICAL COMPOSITIONSJuly 2024September 2024Allow200YesNo
18777570METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSAJuly 2024January 2025Allow610YesNo
18761898MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024January 2025Allow710YesNo
18762128MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024February 2025Allow710YesNo
18760757MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJuly 2024June 2025Abandon1110NoNo
18760150FAST DISINTEGRATING TABLETJuly 2024October 2025Allow1520NoNo
18760549COMPOSITIONS AND METHODS FOR SUNLESS TANNINGJuly 2024January 2025Allow620YesNo
18757727COPPER NANOCLUSTERS, COMPOSITION COMPRISING THE SAME, AND TREATMENT OF MULTIPLE SCLEROSISJune 2024August 2025Allow1410NoNo
18758699MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18759320MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024February 2025Allow710YesNo
18759364MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18758081MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024October 2024Allow410YesNo
18755045MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFJune 2024August 2024Allow210NoNo
18744999Roflumilast Formulations with an Improved Pharmacokinetic ProfileJune 2024November 2024Allow510NoNo
18745572Dry Powdered Compositions and Methods and Uses ThereofJune 2024March 2025Allow900YesNo
18735876CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAMEJune 2024August 2025Allow1410YesNo
18735889CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAMEJune 2024August 2025Allow1410YesNo
18679670INTRANASAL ADMINISTRATION OF ESKETAMINEMay 2024April 2025Abandon1110NoNo
18670960METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSMay 2024June 2025Allow1310NoNo
18671025CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAMEMay 2024August 2025Allow1510YesNo
18667581TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHANMay 2024April 2025Allow1120NoNo
18667925FILM-FORMING COMPOSITION CONTAINING SURFACTANT OR SURFACTANT AND SALT AS WHITENING AGENTMay 2024July 2025Allow1410YesNo
18667326CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAMEMay 2024August 2025Allow1510YesNo
18666141SHELF-STABLE FORMULATIONS OF BENZOYL PEROXIDE AND METHODS OF PRODUCING SAMEMay 2024March 2025Abandon1010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1615.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
395
Examiner Affirmed
279
(70.6%)
Examiner Reversed
116
(29.4%)
Reversal Percentile
34.0%
Lower than average

What This Means

With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
2187
Allowed After Appeal Filing
526
(24.1%)
Not Allowed After Appeal Filing
1661
(75.9%)
Filing Benefit Percentile
14.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1615 - Prosecution Statistics Summary

Executive Summary

Art Unit 1615 is part of Group 1610 in Technology Center 1600. This art unit has examined 17,164 patent applications in our dataset, with an overall allowance rate of 55.3%. Applications typically reach final disposition in approximately 33 months.

Comparative Analysis

Art Unit 1615's allowance rate of 55.3% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1615 receive an average of 2.22 office actions before reaching final disposition (in the 75% percentile). The median prosecution time is 33 months (in the 35% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.